Abstract
Backgrounds The emerging virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a large outbreak of novel coronavirus disease (COVID-19) in Wuhan, China since December 2019. Based on the publicly available surveillance data, we identified 21 transmission chains in Hong Kong and estimated the serial interval (SI) of COVID-19.
Methods Index cases were identified and reported after symptoms onset, and contact tracing was conducted to collect the data of the associated secondary cases. An interval censored likelihood framework is adopted to fit a Gamma distribution function to govern the SI of COVID-19.
Findings Assuming a Gamma distributed model, we estimated the mean of SI at 4.4 days (95%CI: 2.9−6.7) and SD of SI at 3.0 days (95%CI: 1.8−5.8) by using the information of all 21 transmission chains in Hong Kong.
Conclusion The SI of COVID-19 may be shorter than the preliminary estimates in previous works. Given the likelihood that SI could be shorter than the incubation period, pre-symptomatic transmission may occur, and extra efforts on timely contact tracing and quarantine are recommended in combating the COVID-19 outbreak.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
DH was supported by General Research Fund (Grant Number 15205119) of the Research Grants Council (RGC) of Hong Kong, China. WW was supported by National Natural Science Foundation of China (Grant Number 61672013) and Huaian Key Laboratory for Infectious Diseases Control and Prevention (Grant Number HAP201704), Huaian, Jiangsu, China.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email address of all authors SZ: zhaoshi.cmsa{at}gmail.com, DG: dzgao{at}shnu.edu.cn, ZZ: larry.zhuang{at}polyu.edu.hk, MKCC: marc{at}cuhk.edu.hk, YC: yonglicai{at}hytc.edu.cn, JR: jimran{at}connect.hku.hk, PC: cphcc{at}smu.edu.cn, KW: wangkaimath{at}sina.com, YL: yijun.lou{at}polyu.edu.hk, WW: weimingwang2003{at}163.com, LY: l.yang{at}polyu.edu.hk, DH: daihai.he{at}polyu.edu.hk, MHW: maggiew{at}cuhk.edu.hk
Data Availability
We used public available data only.
